The Sound of Evolution
Canagliflozin
Mechanism of action:
Canagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor. Under normal conditions, the kidneys reabsorb nearly all filtered glucose. Approximately 90% of this glucose is reabsorbed through SGLT2 in proximal tubular epithelial cells, while the remaining 10% is reabsorbed by SGLT1. Canagliflozin inhibits the function of SGLT2, preventing glucose reabsorption and causing most of the glucose to be excreted in the urine.
Reference(s):
1. Lamos EM et al. (2013). Canagliflozin, an inhibitor of sodium-glucose cotransporter 2, for the treatment of type 2 diabetes mellitus. Expert Opin Drug Metab Toxicol.
2. Osaki A et al. (2016). Renal threshold for glucose reabsorption predicts diabetes improvement by sodium-glucose cotransporter 2 inhibitor therapy. J Diabetes Investig.